No Data
Gan & Lee Pharmaceuticals (SHSE:603087) Is Posting Healthy Earnings, But It Is Not All Good News
Gan & Lee Pharmaceuticals Doses First Patient in Psoriasis Drug Trial
Gan & Lee Pharmaceuticals (603087.SH): GLR1023 injection completed the first dose administration of the first subject in China Phase I clinical trial.
Gelonghui October 23rd | gan & lee pharmaceuticals (603087.SH) announced that after receiving the "Drug Clinical Trial Approval Notice" for the company's investigational drug GLR1023 injection issued by the National Medical Products Administration, they have initiated Phase I clinical trials in china and recently successfully completed the first subject's dosing. GLR1023 injection is a biosimilar of the marketed pharmaceutical Secukinumab, with a fully human recombinant monoclonal IgG1κ antibody, whose antigen binding site of the Fab segment can bind to human interleukin IL-17.
Gan & Lee Pharmaceuticals Q3 Profit Up 57%; Shares Climb 3%
Third Quarter Report 2024
Overseas income increased, the effects of a new round of follow-up procurement strategies are showing. Net income of gan & lee pharmaceuticals in the first three quarters nearly doubled. | Interpretations of financial reports
1. In the first three quarters of this year, gan & lee pharmaceuticals' domestic and international revenues both increased year-on-year. 2. The company won the insulin special procurement bid, and the revenue growth effect brought by the rise in bid product prices began to show in Q3. 3. The company is attempting to sell insulin products overseas, and the increase in milestone revenue is also one of the factors contributing to the company's performance growth.
Gan & Lee Pharmaceuticals. (SHSE:603087) May Have Run Too Fast Too Soon With Recent 30% Price PlummetNo Data
No Data
